One Kendall Square, Building 1400 West
Cambridge, MA 02139
Microbia Inc.
Microbia Inc. has amassed a large patent portfolio covering novel targets for rendering fungi harmless, disrupting communities of bacteria, and for harnessing these organisms to the task of manufacturing useful products. Well-armed with $59 million in funding and the chemistry skills to turn biological insights into weapons against infectious diseases, Microbia hopes to create new antimicrobial drugs that work in fundamentally different ways than the drugs that are available today.
More from Archive
More from Scrip
• By
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
• By
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
• By
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.